1–2 mg — reported, not studied
1–2 mg a week, split over one or two injections of the drug-affinity-complex version, under the skin. This is reported practice, distinct from the weight-based single and repeated doses in the cited human studies.
| Water added | Concentration | Draw, low to high |
|---|---|---|
| 2 mL | 2.50 mg/mL | 40.0 to 80.0 units |
| 3 mL | 1.67 mg/mL | 60.0 to 120.0 unitswon’t fit |
indirect evidenceDominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol 2026 — tabulates self-reported online dosing patterns beside the clinical doses, stating the reported values must not be read as clinically validated, regulatory-approved or safe · retrieved 2026-08-12
